{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:55:03Z","timestamp":1784876103120,"version":"3.55.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institutes of Health\/the National Cancer Institute","award":["P30CA138292"],"award-info":[{"award-number":["P30CA138292"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lutetium-177 (177Lu)\u2013PSMA-617 is a beta-emitting radioligand approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), despite the underrepresentation of Black patients in pivotal trials. We analyzed outcomes of 177Lu-PSMA-617 in a racially diverse cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of patients with mCRPC treated with 177Lu-PSMA-617 was conducted at the Emory Winship Cancer Institute. Primary outcomes assessed were progression-free survival (PFS), overall survival (OS), and prostate-specific antigen (PSA) reduction \u226550% (PSA50). Cox proportional hazard models were used for univariate and multivariate OS and PFS, and logistic regression was used for PSA50 analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 163 patients treated with 177Lu\u2013PSMA-617, 97 (59.5%) self-identified as White or other racial groups and 66 (40.5%) self-identified as Black. On univariate analysis, Black patients had comparable OS, PFS, and PSA50 responses to non-Black patients, with a trend toward improved outcomes (OS HR: 0.82, P\u2009=\u2009.446; PFS HR 0.92, P\u2009=\u2009.655; PSA50 OR\u2009=\u20091.79, P\u2009=\u2009.088). Multivariate analysis demonstrated a non-significant prolonged PFS and reduction in mortality risk for Black patients (PFS HR: 0.65, P\u2009=\u2009.106; OS: HR 0.59, HR P-value .081). The odds of a PSA50 response were 2.45 times higher for Black patients (OR\u2009=\u20092.45, P\u2009=\u2009.027).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our racially diverse cohort of patients with mCRPC, Black patients had PFS and OS comparable to non-Black patients, although wide confidence intervals limit definitive conclusions. Black patients had a significantly greater odds of achieving a PSA50 response. Our findings suggest efficacy of 177Lu-PSMA-617 among Black patients in real-world settings and underscore the importance of improved representation in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag022","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:44:24Z","timestamp":1769777064000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of lutetium-177\u2013PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9002-7697","authenticated-orcid":false,"given":"Margo Brooke","family":"Gerke","sequence":"first","affiliation":[{"name":"Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Bedmutha","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0004-4027","authenticated-orcid":false,"given":"Angelo","family":"Marra","sequence":"additional","affiliation":[{"name":"Biostatistics Shared Resource, Winship Cancer Institute, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-3058","authenticated-orcid":false,"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline T","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"Nazha","sequence":"additional","affiliation":[{"name":"Piedmont Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob E","family":"Berchuck","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Bharat","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan Alana","family":"Ciuro","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Hartman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta Russler","family":"McClintock","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Caulfield","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley Curtis","family":"Carthon","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Schuster","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Muzahir","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Division of Nuclear Medicine and Molecular Imaging, Emory University , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-1103","authenticated-orcid":false,"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322,","place":["United States"]},{"name":"Emory Winship Cancer Institute , Atlanta, GA 30322,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026030218563483300_oyag022-B1","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"2026030218563483300_oyag022-B2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"2026030218563483300_oyag022-B3","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030218563483300_oyag022-B4","first-page":"33","article-title":"Prostate cancer","volume":"4","author":"Oncology NCPGi","year":"2024","journal-title":"Natl Compr Canc Netw"},{"key":"2026030218563483300_oyag022-B5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2026030218563483300_oyag022-B6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"2026030218563483300_oyag022-B7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s1470-2045(23)00529-6","article-title":"Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026030218563483300_oyag022-B8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"2026030218563483300_oyag022-B9","first-page":"33","year":"2025"},{"key":"2026030218563483300_oyag022-B10","volume-title":"Cancer Facts & Figures for African American\/Black People","author":"Society AC","year":"2023"},{"key":"2026030218563483300_oyag022-B11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11912-020-00966-z","article-title":"Racial disparity in response to prostate cancer systemic therapies","volume":"22","author":"Bitting","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"2026030218563483300_oyag022-B12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/jco.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026030218563483300_oyag022-B13","author":"Bureau USC","year":"2022"},{"key":"2026030218563483300_oyag022-B14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/jco.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026030218563483300_oyag022-B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3322\/caac.21874","article-title":"Cancer statistics for African American and black people","volume":"75","author":"Saka","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026030218563483300_oyag022-B16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/jco.18.01279","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026030218563483300_oyag022-B17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/ju.0000000000000524","article-title":"Racial discrepancies in overall survival among men treated with (223)radium","volume":"203","author":"Zhao","year":"2020","journal-title":"J Urol"},{"key":"2026030218563483300_oyag022-B18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41391-020-0213-7","article-title":"Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry","volume":"23","author":"Sartor","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026030218563483300_oyag022-B19","doi-asserted-by":"publisher","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026030218563483300_oyag022-B20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.clgc.2015.12.003","article-title":"African American participation in oncology clinical trials\u2014focus on prostate cancer: implications, barriers, and potential solutions","volume":"14","author":"Ahaghotu","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"2026030218563483300_oyag022-B21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.123.266842","article-title":"Real-world experience with (177)Lu-PSMA-617 radioligand therapy after Food and Drug Administration approval","volume":"65","author":"Moradi Tuchayi","year":"2024","journal-title":"J Nucl Med"},{"key":"2026030218563483300_oyag022-B22","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2967\/jnumed.124.267723","article-title":"Initial experience with [177Lu]Lu-PSMA-617 after regulatory approval for metastatic castration-resistant prostate cancer: efficacy, safety, and outcome prediction","volume":"65","author":"Gafita","year":"2024","journal-title":"J Nucl Med"},{"key":"2026030218563483300_oyag022-B23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.34749","article-title":"The real-world outcomes of lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish oncology group multicenter study","volume":"154","author":"Almuradova","year":"2024","journal-title":"Int J Cancer"},{"key":"2026030218563483300_oyag022-B24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of Black race with prostate cancer\u2013specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026030218563483300_oyag022-B25","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/HYPERTENSIONAHA.121.17570","article-title":"Racial\/ethnic disparities in hypertension prevalence, awareness, treatment, and control in the United States, 2013 to 2018","volume":"78","author":"Aggarwal","year":"2021","journal-title":"Hypertension"},{"key":"2026030218563483300_oyag022-B26","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1001\/jama.283.17.2253","article-title":"Incident type 2 diabetes mellitus in African American and White adults: the atherosclerosis risk in communities study","volume":"283","author":"Brancati","year":"2000","journal-title":"JAMA"},{"key":"2026030218563483300_oyag022-B27","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1161\/01.Cir.0000158136.76824.04","article-title":"State of disparities in cardiovascular health in the United States","volume":"111","author":"Mensah","year":"2005","journal-title":"Circulation"},{"key":"2026030218563483300_oyag022-B28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1200\/JCO.2022.40.6_suppl.120","article-title":"Community oncologists\u2019 perceptions of and barriers to access for 177LU-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"40","author":"Gajra","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026030218563483300_oyag022-B29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11113-016-9416-y","article-title":"Racial and ethnic disparities in health insurance coverage: dynamics of gaining and losing coverage over the life-course","volume":"36","author":"Sohn","year":"2017","journal-title":"Popul Res Policy Rev"},{"key":"2026030218563483300_oyag022-B30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1370\/afm.748","article-title":"Insurance + access \u2260 health care: typology of barriers to health care access for low-income families","volume":"5","author":"DeVoe","year":"2007","journal-title":"Ann Fam Med"},{"key":"2026030218563483300_oyag022-B31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41391-021-00463-9","article-title":"Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer","volume":"25","author":"George","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026030218563483300_oyag022-B32","doi-asserted-by":"publisher","first-page":"e2142093","DOI":"10.1001\/jamanetworkopen.2021.42093","article-title":"Outcomes among African American and non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone","volume":"5","author":"Marar","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026030218563483300_oyag022-B33","doi-asserted-by":"publisher","first-page":"dju002","DOI":"10.1093\/jnci\/dju002","article-title":"Comparison of survival outcomes among cancer patients treated in and out of clinical trials","volume":"106","author":"Unger","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2026030218563483300_oyag022-B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12963-020-00244-x","article-title":"Comparisons of individual- and area-level socioeconomic status as proxies for individual-level measures: evidence from the mortality disparities in American Communities study","volume":"19","author":"Moss","year":"2021","journal-title":"Popul Health Metr"},{"key":"2026030218563483300_oyag022-B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/diagnostics11040663","article-title":"Concordance between response assessment using prostate-specific membrane antigen PET and serum prostate-specific antigen levels after systemic treatment in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Han","year":"2021","journal-title":"Diagnostics (Basel)"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag022\/66719713\/oyag022.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag022\/66719713\/oyag022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/3\/oyag022\/66719713\/oyag022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T23:56:45Z","timestamp":1772495805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag022\/8455777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag022","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,3]]},"article-number":"oyag022"}}